Skip to main content
    S

    Salarius Pharmaceuticals Inc (SLRX)

    Official site

    BIOTECHNOLOGY

    $0.84
    +0.19 (+29.23%)

    Last updated: Jan 07, 2026 at 4:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(23/36)
    Avg Surprise
    -132.86%
    PeriodReportedEst.SurpriseB/MYoY
    Sep 25
    Reported Nov 14
    		$-1.81$-1.01-79.21%Miss+84.1%
    Jun 25
    Reported Aug 12
    		$-0.45N/A+55.88%Beat+81.0%
    Mar 25
    Reported May 12
    		$-1.02$-1.03+1.38%Beat-147.8%
    Dec 24
    Reported Mar 21
    		$-1.01$-0.74-36.49%Miss-359.1%
    Sep 24
    Reported Nov 14
    		$-11.40N/A+98.58%Beat-1653.8%
    Jun 24
    Reported Aug 9
    		$-2.37N/A+95.58%Beat-65.7%
    Mar 24
    Reported May 13
    		$-0.41N/A+93.88%Beat+81.6%
    Dec 23
    Reported Mar 22
    		$-0.22N/A+78.22%Beat+92.2%
    Sep 23
    Reported Nov 9
    		$-0.65$-1.20+45.83%Beat+73.7%
    Jun 23
    Reported Aug 10
    		$-1.43$-1.30-10.00%Miss+36.4%
    Mar 23
    Reported May 11
    		$-2.23$-2.50+10.80%Beat+31.4%
    Dec 22
    Reported Mar 27
    		$-2.83$-2.15-31.63%Miss-25.8%
    Sep 22
    Reported Nov 10
    		$-2.47$-2.55+3.14%Beat-23.5%
    Jun 22
    Reported Aug 5
    		$-2.25$-2.62+14.12%Beat-28.6%
    Mar 22
    Reported May 12
    		$-3.25$-2.25-44.44%Miss-116.7%
    Dec 21
    Reported Mar 10
    		$-2.25$-2.12-6.13%Miss+10.0%
    Sep 21
    Reported Nov 4
    		$-2.00$-1.62-23.46%Miss+20.0%
    Jun 21
    Reported Aug 5
    		$-1.75$-1.42-23.24%Miss+46.2%
    Mar 21
    Reported May 12
    		$-1.50$-1.37-9.49%Miss+72.7%
    Dec 20
    Reported Mar 18
    		$-2.50$-2.75+9.09%Beat-468.2%
    Sep 20
    Reported Nov 11
    		$-2.50$-2.62+4.58%Beat-242.5%
    Jun 20
    Reported Aug 12
    		$-3.25$-4.12+21.12%Beat-69.3%
    Mar 20
    Reported May 14
    		$-5.50$-11.00+50.00%Beat-102.2%
    Dec 19
    Reported Mar 23
    		$-0.44N/A+84.00%Beat+84.0%
    Sep 19
    Reported Nov 13
    		$-0.73N/A+73.45%Beat+80.5%
    Jun 19
    Reported Aug 5
    		$-1.92$-3.50+45.14%Beat+99.4%
    Mar 19
    Reported May 1
    		$-2.72$-0.19-1331.58%Miss+99.1%
    Dec 18
    Reported Mar 6
    		$-2.75$-0.11-2400.00%Miss+99.0%
    Sep 18
    Reported Nov 5
    		$-3.75$-0.21-1685.71%Miss+98.9%
    Jun 18
    Reported Aug 1
    		$-312.50$-281.25-11.11%Miss+2.0%
    Mar 18
    Reported May 2
    		$-287.50$-303.12+5.15%Beat-9.5%
    Dec 17
    Reported Mar 7
    		$-287.50$-356.25+19.30%Beat-15.0%
    Sep 17
    Reported Nov 6
    		$-337.50$-378.12+10.74%Beat-
    Jun 17
    Reported Aug 2
    		$-318.75$-359.37+11.30%Beat-
    Mar 17
    Reported May 3
    		$-262.50$-387.50+32.26%Beat-
    Dec 16
    Reported Mar 8
    		$-250.00$-462.50+45.95%Beat-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.66
    SMA 20$0.70
    SMA 50$1.36
    SMA 200N/A
    EMA 10$0.68
    EMA 20$0.76
    EMA 50$1.54
    EMA 200$5.55

    MACD

    Line: -0.18Signal: -0.25Hist: 0.07

    ADX

    ADX: 26.7+DI: 30.7-DI: 25.4

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down92.0
    PSAR$0.51

    Bollinger Bands

    Upper Band$0.87
    Lower Band$0.53
    %B Position4961%(Upper)
    Band Width0.90

    RSI (14-Day)

    Neutral
    47.3

    Momentum Oscillators

    Stoch %K43.9
    Stoch %D24.1
    Williams %R-15.0
    ROC (10d)26.0%
    Momentum0.17
    CCI (20d)93.7
    MFI (14d)72.4

    Volatility Measures

    ATR (14d)$0.12(14.2%)
    StdDev (20d)0.09
    Hist Vol159.0%(High)

    Volume Flow

    VWAP$0.81
    OBV211.1M
    AD Line17.6B
    CMF (20d)0.109

    Volume Metrics

    Avg Vol (20d)645.1K
    Vol Ratio9.4x(High)
    VWMA (20d)$0.75

    Pivot Points

    R3$0.84
    R2$0.75
    R1$0.70
    Pivot Point$0.61
    S1$0.56
    S2$0.46
    S3$0.41

    Advanced Oscillators

    TSI-41.95
    Ultimate Osc55.7
    KST-322.13

    Financial Data

    QuarterSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total Revenue$0$0$0$4,426$0$0$0$17,892$0$0$0$0
    Cost of Revenue$1,106$1,106$1,106$2,213$1,105$1,106$1,107$1,105$5,608$1,669$1,669$1,669
    Gross Profit$-1,106$-1,106$-1,106$2,213$-1,105$-1,106$-1,107$16,787$-5,608$-1,669$-1,669$-1,669
    Operating Expenses$894,024$965,565$1.72M$1.49M$1.01M$1.47M$1.77M$970,701$2.53M$3.97M$5.42M$6.48M
    R&D$61,826$116,383$75,532$175,344$137,234$214,447$243,000$59,953$1.04M$2.35M$3.73M$4.69M
    SG&A$833,304$849,182$1.64M$1.31M$869,237$1.25M$1.53M$910,748$1.50M$1.62M$1.70M$1.79M
    Operating Income$-895,130$-965,565$-1,718,695$-1,488,713$-1,006,471$-1,467,517$-1,771,615$-970,701$-2,532,185$-3,971,395$-5,420,663$-6,477,880
    Interest Income$21,663$0$9,162$24,780$34,350$0$56,325$88,905$89,369$0$79,890$92,490
    Interest Expense$0$0$0$0$0$0$0$79,890$0$0$79,890$111,474
    Income Before Tax$-873,467$-957,825$-1,709,533$-1,463,933$-972,121$-1,424,433$-1,715,290$-881,796$-2,442,816$-3,877,308$-5,340,773$-6,370,936
    Income Tax Expense$0$0$0$0$0$4$3$-5$-89,369$-120,416$-79,890$111,474
    Net Income$-873,467$-957,825$-1,709,533$-1,463,933$-972,121$-1,424,433$-1,715,290$-881,796$-2,442,816$-3,877,308$-5,340,773$-6,370,936
    EBITDA$-872,361$-964,459$-1,717,589$-1,487,607$-1,005,366$-1,466,411$-1,770,508$-969,596$-2,526,577$-3,969,726$-5,418,994$-6,476,211
    EBIT$-873,467$-965,565$-1,718,695$-1,488,713$-1,006,471$-1,467,517$-1,771,615$-970,701$-2,532,185$-3,971,395$-5,420,663$-6,477,880
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SLRX

    News

    Form S-1 Decoy Therapeutics Inc For: 8 October By Investing.com

    This article announces that Decoy Therapeutics Inc. filed a Form S-1 on October 8, 2026. The filing is a regulatory document typically submitted by companies planning to go public in the United States. The article...

    Investing.com Nigeria•10/9/26•Neutral

    Form S-1 Decoy Therapeutics Inc For: 8 October By Investing.com

    This article announces the filing of Form S-1 by Decoy Therapeutics Inc. on October 8th. The brief piece indicates this is a financial filing relevant to stock market observers and includes the stock symbol DCOY.

    Investing.com UK•10/8/26•Neutral

    Form S-1 Decoy Therapeutics Inc For: 8 October By Investing.com

    This article announces the filing of Form S-1 by Decoy Therapeutics Inc. on October 8th. It is a brief news item from Investing.com...

    Investing.com India•10/8/26•Neutral

    Form S-1 Decoy Therapeutics Inc For: 8 October By Investing.com

    This article announces the filing of Form S-1 by Decoy Therapeutics Inc. on October 8th, as reported by Investing.com. The content primarily focuses on general financial market data, indices, commodities...

    Investing.com Canada•10/7/26•Neutral

    Decoy Therapeutics to Present at The Small Cap Showcase

    Decoy Therapeutics announced that CEO Rick Pierce will present at The Small Cap Showcase on Thursday, October 1, 2026...

    GlobeNewswire•9/30/26•Neutral

    SLRX Competitors

    CompanyTicker
    Tivic Health Systems IncTIVC
    Inotiv IncNOTV
    CERo Therapeutics Holdings, Inc. Common StockCERO
    Safeplus International Holdings LimitedBIPH
    Venus Concept IncVERO
    Vicarious Surgical Inc.RBOT
    Profusa, Inc. Common StockPFSA
    Catheter Precision Inc.VTAK

    Sector: Healthcare

    SLRX Bull Case vs Bear Case

    Bull case

    • SLRX beat EPS estimates in 75.0% of its last 8 reported quarters.

    SLRX Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    38.5%

    Frequently Asked Questions About SLRX

    Does SLRX pay dividends?

    Salarius Pharmaceuticals Inc (SLRX) does not currently pay a regular dividend.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In